Nrf-2-SLC7A11-GSH pathway

Overview

The Nrf-2-SLC7A11-GSH pathway refers to a redox-regulatory signaling axis centered on Nrf2 (nuclear factor erythroid 2–related factor 2), SLC7A11 (the cystine/glutamate antiporter subunit xCT), and glutathione (GSH). In biomedical research, this pathway is commonly discussed as a functional module that controls cellular antioxidant capacity, cystine uptake, glutathione synthesis, and resistance or susceptibility to oxidative stress. By promoting SLC7A11 expression, Nrf2 can support intracellular cystine import and GSH production, thereby helping cells neutralize reactive oxygen species and limit lipid peroxidation.

This pathway is especially important in studies of ferroptosis, a regulated form of cell death driven by iron-dependent lipid peroxidation. When Nrf2-SLC7A11-GSH signaling is suppressed, cells may become more vulnerable to oxidative injury and ferroptotic death; when it is activated, cells often show improved antioxidant defense. As a result, the pathway is frequently investigated in cancer, neuroprotection, inflammatory injury, and metabolic stress, including contexts involving GPX4, reactive oxygen species, superoxide dismutase, MDA, and related oxidative stress markers.

Focus of Latest Publications

Recent publications have extensively characterized the Nrf2-SLC7A11-GSH pathway as a central regulator of cellular redox homeostasis and ferroptosis resistance across multiple disease contexts. The pathway functions through Nrf2-dependent transcriptional upregulation of SLC7A11 (also designated xCT), a cystine/glutamate antiporter that supplies cystine for intracellular glutathione (GSH) synthesis. GSH acts as a critical cofactor for glutathione peroxidase 4 (GPX4), which catalyzes the reduction of lipid peroxides and suppresses ferroptotic cell death. Multiple studies demonstrated that pharmacological activation of Nrf2 by compounds including omaveloxolone, 10-shogaol, carvacrol, and thymol nanoparticles upregulated SLC7A11 expression and antioxidant proteins (including NQO1, HO-1, and SOD2), thereby enhancing cellular cytoprotection in models of spinal muscular atrophy, viral infection, doxorubicin cardiotoxicity, and chemotherapy-induced cognitive impairment. The capacity of Nrf2 to coordinate transcriptional programs maintaining redox balance extended to other contexts: liraglutide-mediated activation of the GLP-1R/NRF2 pathway suppressed oxidative stress and NLRP3 inflammasome components in postoperative cognitive dysfunction, while warm kidney and spleen granules activated Nrf2/HO-1 signaling to alleviate diabetic diarrhea.

Conversely, therapeutic targeting of the Nrf2-SLC7A11-GSH axis proved effective for inducing ferroptotic cancer cell death and overcoming drug resistance. paclitaxel and sunitinib co-treatment synergistically downregulated SLC7A11 and GPX4 while upregulating the pro-ferroptotic enzyme ACSL4, with SLC7A11 identified as a critical mediator of therapeutic sensitivity in lung cancer. Similarly, Paris polyphylla saponin induced autophagy-dependent ferroptosis in cervical cancer cells by suppressing the BECLIN1/SLC7A11 axis, while Scutellaria barbata exosome-like nanovesicles promoted ferroptosis in hepatocellular carcinoma through direct inhibition of the Nrf2/SLC7A11/GPX4 pathway. A self-propelled molecular rocket releasing triptolide exploited the pathway's cytoprotective function in reverse, inducing ferroptosis and apoptosis via disruption of the Nrf-2-SLC7A11-GSH axis to enhance Herceptin efficacy in drug-resistant breast cancer. Engineered mesenchymal stem cell exosomes overexpressing miR-142a-3p similarly targeted the GSK3β/Nrf2/SLC7A11 axis to suppress ferroptosis and oxidative stress in osteoarthritis, demonstrating the pathway's relevance to degenerative joint disease.

Additional mechanisms of pathway engagement revealed complex cross-talk between Nrf2 regulation and disease-specific pathology. Advanced glycation end-products impaired mitochondrial antioxidant defense through the RAGE-Nrf2-SOD2 axis in myocardial ischemia/reperfusion injury, while HIF-1α upregulation interacted with SLC7A11 suppression to impair microglial efferocytosis in sepsis-associated encephalopathy. Pterostilbene inhibited ferritinophagy-mediated ferroptosis via the NRF2/NCOA4/FTH1 axis in intervertebral disc degeneration, implicating iron metabolism regulators as downstream effectors. These studies collectively establish the Nrf2-SLC7A11-GSH pathway as a versatile therapeutic target: activation confers broad cytoprotection against oxidative stress and multiple acute and chronic diseases, while inhibition or dysregulation of pathway components provides a strategy for ferroptosis-based cancer therapy and overcoming therapeutic resistance.

Key Publications

• NEWJun Wedelactone-loaded exosomes for sepsis-induced liver injury: a novel therapeutic strategy. (Drug delivery, 2026, PMID 42381381): "Importantly, pharmacological inhibition of ML385, a selective Nrf2 inhibitor, confirmed the critical regulatory role of the Nrf2 pathway in mediating these multifaceted liver protective effects."
• NEWJun Advances in glutathione biosynthesis and industrialization. (Sheng wu gong cheng xue bao = Chinese journal of biotechnology, 2026, PMID 42343788): "It is used in the multiple fields such as pharmaceuticals, food, cosmetics, and feed additives."
• NEWJun Reversible Disorder-to-Order Transition of Coacervates for Tumor Microenvironment-Responsive Intracellular Drug Delivery. (ACS nano, 2026, PMID 42312698): "In contrast, elevated acidity and glutathione (GSH) levels, characteristics of the tumor microenvironment (TME), trigger a reverse order-to-disorder transition and dissolution of coacervates for on-demand drug release."
• NEWJun Pharmacological Activation of NRF2 by Omaveloxolone Upregulates NRF2-Target Proteins in SMA Type I Human Fibroblasts. (FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026, PMID 42301137): "Since NRF2 coordinates transcriptional programs that maintain cellular redox homeostasis and adaptive stress responses, we investigated whether NRF2 signaling is similarly altered in fibroblasts derived from individuals with SMA type I and whether it can be pharmacologically engaged."
• NEWJun Discovery of 10-Shogaol from Zingiber officinale with Broad Antiviral and Anti-inflammatory Activity against Dengue and Zika Viruses Using Activity-Guided Molecular Networking. (Journal of agricultural and food chemistry, 2026, PMID 42270434): "Additionally, 10-shogaol suppressed proinflammatory cytokines and mitigated tissue damage in mice by acting as a novel Nrf2 activator by inhibiting Keap1-mediated ubiquitination and proteasome degradation."
• NEWJun Exosomal MALAT1 expression associated with the cardioprotective effects of carvacrol in acute doxorubicin-induced cardiac injury: Potential involvement of Nrf2/Keap1-related signaling. (Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026, PMID 42259137): "Nrf2, Keap1, and extracellular vesicle-associated MALAT1 expression levels were evaluated using quantitative PCR."
• May RAD1 promotes oxaliplatin resistance in gastric cancer by reinforcing NRF2-driven antioxidant defense and DDR checkpoint signaling. (Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2026, PMID 42217457): "RAD1 promotes oxaliplatin resistance in gastric cancer by reinforcing NRF2-driven antioxidant defense and DDR checkpoint signaling."
• May A catalytic redox-cycling nanoreactor enables robust oxidative stress amplification for synergistic tumor apoptosis and ferroptosis. (Acta biomaterialia, 2026, PMID 42217658): "Mechanistically, T@cLAN depletes intracellular glutathione (GSH) and undergoes depolymerization to generate dihydrolipoic acid (DHLA), which actively participates in redox processes to enhance ROS production."
• May DIA-based proteomic analysis reveals Scutellaria barbata D. Don Exosome-like nanovesicles promote ferroptosis in HCC through Nrf2/SLC7A11/GPX4 pathway. (Functional & integrative genomics, 2026, PMID 42209785): "The ferroptosis effect induced by SBENs in HepG2 cells is marked by mitochondrial depolarization, elevated Fe²⁺, MDA, ROS, depleted GSH, and reduced SLC7A11/GPX4 expression."
• May Thymol nanoparticles ameliorate oxaliplatin-induced cognitive impairment via modulation of Nrf2/HO-1, endoplasmic reticulum stress, and NLRP3 inflammasome signaling in rats. (Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026, PMID 42202464): "THY mitigated oxidative stress and endoplasmic reticulum stress as evident from its effect on Nrf2/HO-1 and GRP78/ATF6/CHOP axes."